Examkin

Question

Difficulty: HardInfectious Diseases

A 62-year-old man is evaluated in the hospital on hospital day 3. He was initially admitted for high fever and rigors. His past medical history is significant for end-stage renal disease requiring hemodialysis via a right internal jugular tunneled catheter. Upon admission, peripheral and catheter-drawn blood cultures were obtained, and he was started on empiric antimicrobial therapy with intravenous vancomycin and piperacillin-tazobactam. Today, his temperature is 37.2°C (99.0°F), blood pressure is 128/76 mmHg, and heart rate is 82/min. The admission blood cultures are now positive for Staphylococcus aureus in 4 out of 4 bottles. Susceptibility testing reveals the isolate is resistant to penicillin, but susceptible to oxacillin, cefazolin, and vancomycin. A review of the patient's medical record indicates a documented allergy to amoxicillin, which the patient describes as a 'flat, red skin rash' that occurred several days into a treatment course 10 years ago, without associated pruritus, facial swelling, or difficulty breathing. Which of the following is the most appropriate modification to his current pharmacotherapy?

  1. Transition to intravenous cefazolin monotherapyAnswer
  2. B
    De-escalate to intravenous vancomycin monotherapy
  3. C
    De-escalate to intravenous piperacillin-tazobactam monotherapy
  4. D
    Transition to intravenous daptomycin monotherapy
  5. E
    Transition to intravenous clindamycin monotherapy

Answer

Transition to intravenous cefazolin monotherapy.
The patient has Methicillin-Susceptible Staphylococcus aureus (MSSA) bacteremia, as evidenced by the susceptibility to oxacillin. The standard of care for MSSA endovascular infections and bacteremia dictates the use of a narrow-spectrum beta-lactam, such as an anti-staphylococcal penicillin (nafcillin, oxacillin) or a first-generation cephalosporin (cefazolin). These agents are definitively superior to vancomycin, providing faster bacterial clearance, lower rates of relapse, and reduced mortality. The patient's reported amoxicillin allergy—a delayed, flat, non-itchy rash—is characteristic of a non-IgE mediated (Type IV) mild hypersensitivity or a viral-antibiotic interaction, not true anaphylaxis. Furthermore, cefazolin has a unique R1 side chain that does not cross-react with other penicillins or cephalosporins. Therefore, it is entirely safe and represents the optimal stewardship choice for definitive therapy.

Step-by-Step Solution

1
Interpret the blood culture and susceptibility results.
The pathogen is Staphylococcus aureus that is susceptible to oxacillin, confirming it is Methicillin-Susceptible Staphylococcus aureus (MSSA).
Accurate pathogen identification and resistance profiling dictate the definitive antimicrobial choice.
2
Determine the optimal class of antibiotics for MSSA bacteremia.
Anti-staphylococcal penicillins (e.g., nafcillin, oxacillin) or first-generation cephalosporins (e.g., cefazolin) are the superior agents.
Clinical data consistently demonstrate that beta-lactams yield faster clearance and lower mortality rates for MSSA bacteremia compared to vancomycin.
3
Evaluate the patient's reported penicillin allergy and assess cross-reactivity risk.
The patient describes a delayed, non-pruritic maculopapular rash, which is a mild, non-IgE mediated reaction. Cefazolin has a distinct R1 side chain and negligible cross-reactivity with penicillins.
Understanding allergy phenotypes prevents unnecessary avoidance of first-line therapies. A mild delayed rash is not a contraindication to cefazolin.

Key Concept

For Methicillin-Susceptible Staphylococcus aureus (MSSA) bacteremia, narrow-spectrum beta-lactams (like cefazolin or nafcillin) are superior to vancomycin. A history of a mild, non-IgE mediated delayed rash to penicillin is not a contraindication to cefazolin therapy.
Rate this question

Topics

Infectious Diseases

More questions from this topic